Estrogen receptor alpha variants and methods of detection thereof
CA 2426405 A1 · Owner: Winn-Deen, Emily S. · Inventors: Kalush, Francis; Cassel, Michael J.; Hwang, Stuart Soo-In
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based on sequencing genomic DNA from human chromosome 6 and cDNAs to define the genomic structure of estrogen receptor alpha genes and novel polymorphism/haplotypes in the estrogen receptor gene/protein. Such polymorphism/haplotypes can lead to a variety of disorders that are mediated/modulated by a variant estrogen receptor such as a susceptibility to , cancer, osteoporosis cardiovascular disorder, etc. Based on this sequencing approach, the present invention provides genomic nucleotide sequences cDNA , sequences, amino acid sequences and sequence polymorphism/haplotypes in the ESR-alpha genes, methods of detecting these sequences/polymorphism/haplotypes in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 21, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 21, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 21, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.